Sichuan University
Clinical trials sponsored by Sichuan University, explained in plain language.
-
New combo therapy aims to slow advanced lung cancer
Disease control OngoingThis study tests a new treatment for people with extensive-stage small cell lung cancer who have not had prior treatment. It combines low-dose radiation with standard chemotherapy and an immunotherapy drug called serplulimab. The goal is to see if this combination can delay cance…
Phase: PHASE2 • Sponsor: Sichuan University • Aim: Disease control
Last updated May 17, 2026 04:10 UTC
-
New radiation combo shows promise for tough lung cancers
Disease control OngoingThis early-phase study tests whether combining low-dose radiation with targeted radiation (SBRT) and an immunotherapy drug (PD-1 inhibitor) is safe for people with advanced non-small cell lung cancer who have not responded to standard treatments. Nine participants will receive th…
Phase: PHASE1 • Sponsor: Sichuan University • Aim: Disease control
Last updated May 17, 2026 04:00 UTC
-
New combo therapy shows promise for tough lung cancer
Disease control OngoingThis study tests a new treatment for people with extensive-stage small cell lung cancer who haven't had treatment before. It combines a bispecific antibody (AK104) with chemotherapy and low-dose radiation to see if it's safe and helps control the cancer. About 57 adults aged 18 t…
Phase: PHASE1, PHASE2 • Sponsor: Sichuan University • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
Promising lung cancer combo study pulled before starting
Disease control TerminatedThis study was designed to test the safety and tolerability of a new treatment combination for people with extensive-stage small cell lung cancer who had not received prior treatment. The approach combined low-dose radiation with standard chemotherapy and two immunotherapy drugs …
Phase: PHASE1 • Sponsor: Sichuan University • Aim: Disease control
Last updated May 11, 2026 20:40 UTC